Abbott Laboratories

$ 73.92 1.04 (1.43%)
Volume: 9,712,196 Avg Vol (1m): 5,680,004
Market Cap $: 129.84 Bil Enterprise Value $: 145.52 Bil
P/E (TTM): 56.43 P/B: 4.25
Earnings Power Value 41.51
Net Current Asset Value -12.54
Tangible Book -6.65
Projected FCF 31.3
Median P/S Value 38.52
Graham Number 0
Peter Lynch Value 7.06
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 6/10

Current vs industry vs history
Cash-to-Debt 0.21
Equity-to-Asset 0.45
Debt-to-Equity 0.64
Debt-to-EBITDA 2.80
Interest Coverage 4.42
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.39
DISTRESS
GREY
SAFE
Beneish M-Score -2.73
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 6.17%
WACC 6.9%

Profitability & Growth : 7/10

Current vs industry vs history
Operating Margin % 11.94
Net Margin % 7.74
ROE % 7.68
ROA % 3.34
ROC (Joel Greenblatt) % 37.49
3-Year Total Revenue Growth Rate 14.40
3-Year Total EBITDA Growth Rate 13.10
3-Year EPS w/o NRI Growth Rate -8.70

» ABT's 30-Y Financials

Financials (Next Earnings Date: 2019-07-18)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:ABT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Devices » Medical Devices    NAICS : 339112    SIC : 3841
Compare NYSE:MDT NYSE:SYK NAS:ISRG NYSE:BSX NYSE:EW NYSE:ZBH NAS:ALGN LSE:SN. NAS:ABMD NYSE:TFX XSWX:SOON NYSE:VAR SZSE:300003 OCSE:WDH XPAR:DIM ASX:COH LSE:CTEC NZSE:FPH NYSE:GMED OCSE:AMBU B
Traded in other countries ABTT34.Brazil ABL.Germany 0Q15.UK
Address 100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, coronary stents, catheters, infant formula, nutritional liquids for adults, vessel closure devices, and Lasik equipment. Abbott derives approximately 60% of sales outside the United States.

Ratios

Current vs industry vs history
PE Ratio (TTM) 55.58
Forward PE Ratio 22.94
N/A
PE Ratio without NRI 56.43
Price-to-Owner-Earnings 29.15
PB Ratio 4.25
PS Ratio 4.28
Price-to-Free-Cash-Flow 26.68
Price-to-Operating-Cash-Flow 20.78
EV-to-EBIT 39.34
EV-to-EBITDA 20.86
EV-to-Revenue 4.76
PEG Ratio 9.25
Shiller PE Ratio 30.69
Current Ratio 1.62
Quick Ratio 1.20
Days Inventory 107.54
Days Sales Outstanding 61.86
Days Payable 85.46

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 1.62
Dividend Payout Ratio 0.86
3-Year Dividend Growth Rate (Per Share) 5.30
Forward Dividend Yield % 1.73
N/A
Yield-on-Cost (5-Year) % 2.91
3-Year Share Buyback Rate -6.00

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 2.36
Price-to-Median-PS-Value 1.92
Price-to-Peter-Lynch-Fair-Value 10.48
Earnings Yield (Joel Greenblatt) % 2.54
Forward Rate of Return (Yacktman) % 8.10

More Statistics

Revenue (TTM) (Mil) $ 30,578
EPS (TTM) $ 1.33
Beta 0.88
Volatility % 16.84
52-Week Range $ 56.81 - 80.74
Shares Outstanding (Mil) 1,756.47

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N